Pharmaceuticals

Alpha Biopharma Submits New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-mutated NSCLC Patients with CNS Metastases

SHANGHAI, Jan. 29, 2023 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs, announces that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Zorifertinib, a next-generation EGFR-TKI specially ...

2023-01-30 10:00 2841

Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results

* Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit ofKRW 312.8 billion. * FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit ofKRW 983.6 billion. * Strong growth momentum expected to continue with active expansions in capacity, geography, an...

2023-01-27 14:52 4725

Malaysian Society of Plastic and Reconstructive Surgery to host extensive networking and learning event for plastic surgeons and residents

The two-day symposium will have its core focus on cosmetic breast surgery, with two live surgical demonstrations. CPD points to be given to all participating surgeons. KUALA LUMPUR, Malaysia, Jan. 27, 2023 /PRNewswire/ --  The Malaysian Society for Plastic and Reconstructive Surgery (MSPRS) is s...

2023-01-27 08:00 5109

Fosun International Wins Platinum Award at The Asset ESG Corporate Awards 2022

HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Fosun International Limited ("Fosun International" or the "Company") (HKEX: 00656) was informed byThe Asset, the renowned international asset management and investment magazine, that Fosun has garnered the Platinum Award at The Asset ESG Corporate Awards 2...

2023-01-26 14:59 5122

SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane

* First Generic of Abraxane in Korea, World 4th Commercial Scale-Up * Global tech-transfer expected to US, Japan, and Europe SEONGNAM, South Korea ,Jan. 26, 2023 /PRNewswire/ -- SN BioScience (CEO Park Young-hwan) and Boryeong (CEOJang Doo-hyun) signed a domestic manufacturing technology transf...

2023-01-26 14:31 3210

iNtRON has confirmed the efficacy of BAL200, a novel endolysin biologic for Inhalational Anthrax

* Confirmed antibacterial efficacy against a variety of anthrax strains including the one used in the 2001 anthrax attack * Provides the most potent bactericidal ability that no other PEP antibiotics in the market can exhibit * Further developments are planned to conduct with a licensing/col...

2023-01-26 10:34 2716

Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea

"Expected to change GERD drug market landscape" * Application for product approval of Fexuclue, a new drug for gastroesophageal reflux disease (GERD), has been completely submitted toColombia ,Vietnam, and Saudi Arabia * NDA submissions in 11 countries completed in the shortest time among K...

2023-01-26 09:14 3824

Singleron launches single cell eQTL analysis as part of their sequencing service

A new bioinformatic pipeline to investigate single cell eQTL analysis is now offered in the sequencing service from Singleron Biotechnologies. COLOGNE, Germany, Jan. 25, 2023 /PRNewswire/ -- Bioinformatic experts at Singleron Biotechnologies , a leader in single cell sequ...

2023-01-25 19:00 2704

Malaysia Healthcare Partners with AirAsia

Cambodian Passengers Can Kickstart 2023 with Wellness Travel to Malaysia PHNOM PENH, Cambodia, Jan. 25, 2023 /PRNewswire/ -- In its pursuit to providing accessible preventive healthcare and wellness options for global citizens, Malaysia Healthcare Travel Council (MHTC) partners with AirAsia, off...

2023-01-25 14:05 5003

CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

SHANGHAI, Jan. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thata poster presentation highlighting the Phase 1 preliminary result...

2023-01-20 21:50 5555

A Healthy Winter Action: Second Batch of 19,600 Bottles of Azvudine Delivered to 24 Counties

COVID-19 Prevention and Treatment Live-Streaming Training for Rural Doctors Attracted over 1 Million Views HONG KONG, Jan. 20, 2023 /PRNewswire/ -- On January 16, the second stage of "A Healthy Winter Action" initiated by Fosun Foundation in conjunction with other institutions kicked off, with 1...

2023-01-20 18:12 5961

DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma with HER2 Overexpression

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Jan. 20, 2023 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers and autoimmune diseases, announced that the U.S. Food...

2023-01-20 18:00 4226

$412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases

SAN DIEGO, Jan. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced its wholly-owned subsidiary Mabwell Therapeutics has entered into an agreement with DISC MEDICINE, INC. ("Disc") about 9MW3011 (R&D code in t...

2023-01-20 09:50 3321

NEW THERAPY TO TREAT RARE GASTROINTESTINAL STROMAL TUMOUR APPROVED FOR NEW ZEALAND PATIENTS

* QINLOCK® (ripretinib) now Medsafe approved for GIST patients in NZ * QINLOCK now being considered by PHARMAC for reimbursement * Data from the INVICTUS Phase 3 study shows QINLOCK reduces risk of disease progression or death by 85%1, 2 SINGAPORE and AUCKLAND, New Zealand, Jan. 19, 2023 /PR...

2023-01-20 02:00 3269

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global De...

2023-01-19 23:05 7027

Tigermed Completes Acquisition of Marti Farm

HANGZHOU, China and ZAGREB, Croatia, Jan. 19, 2023 /PRNewswire/ -- Tigermed (300347.SZ/3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, announced today the completion of its acquisition of Marti F...

2023-01-19 14:59 5710

China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

SUZHOU, China, and ROCKVILLE, MD, Jan. 18, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), today an...

2023-01-19 11:45 3100

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

ROCKVILLE, Md. and SUZHOU, China, Jan. 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...

2023-01-18 21:34 4935

Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster

GAITHERSBURG, Md., Jan. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner SK bioscience has received expanded manufacturing and marketing...

2023-01-18 21:00 4325

Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services

EAST RUTHERFORD, N.J., Jan. 18, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has completed its acquisition of Snap...

2023-01-18 19:00 3913
1 ... 259260261262263264265 ... 351